Processa (PCSA) Director Retracts Erroneous Form 4, Reports Holdings

Rhea-AI Filing Summary

Processa Pharmaceuticals (PCSA) insider amendment: This amended Form 4, filed by Director Justin W. Yorke, corrects a prior filing submitted in error and reports changes in his holdings. The filing shows a disposition of 3,737 shares of common stock on 07/24/2025. After the reported transactions, Yorke beneficially owns 12,400 shares indirectly via a Directed Trust Company account for his IRA and 31,232 shares indirectly via Richland Fund, LLC. The amendment also reports warrants exercisable for common stock at a $0.65 price 01/29/2030) associated with the Directed Trust Company IRA: 12,400 and 6,200 underlying shares respectively. The form is signed by attorney-in-fact John J. Wolfel on behalf of Yorke.

Positive

• Amendment retracts prior erroneous Form 4, restoring accurate public disclosure
• Clear reporting of indirect holdings and warrants (12,400 and 31,232 shares; warrants at $0.65 expiring 01/29/2030)

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Amendment corrects an error and clarifies insider holdings; disclosure improves governance transparency.

The amended Form 4 indicates a corrective filing rather than a new material event. Retracting the prior Form 4 and restating holdings demonstrates remediation of a reporting mistake and restores accurate public records of a director's beneficial ownership. The filing details both direct dispositions and indirect holdings through trust and fund vehicles, plus outstanding warrants with explicit exercise price and expiration, which are important for assessing potential dilution. Overall, this is a governance housekeeping action with limited market impact.

Securities Analyst

TL;DR: Director sold 3,737 shares; indirect holdings and warrants remain significant but this amendment is routine.

The report records a disposition of 3,737 shares and confirms indirect beneficial ownership of 12,400 and 31,232 shares via IRA trust and an LLC respectively. It also lists warrants exercisable at $0.65 expiring 01/29/2030 for 12,400 and 6,200 underlying shares. These details are pertinent for cap table and dilution analysis, but the amendment itself is corrective and does not present new operational or financial information about the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Yorke Justin W

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								3,737	D
Common Stock								12,400	I	By Directed Trust Company FBO Justin Yorke IRA
Common Stock								31,232	I	By Richland Fund, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.65							01/29/2025	01/29/2030	Common Stock	12,400		12,400	I	By Directed Trust Company FBO Justin Yorke IRA
Warrants	$0.65							01/29/2025	01/29/2030	Common Stock	6,200		6,200	I	By Directed Trust Company FBO Justin Yorke IRA

Explanation of Responses:

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.

	/s/ Justin W. Yorke by John J. Wolfel, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change did the PCSA Form 4/A filed by Justin Yorke report?

The amendment retracts a prior erroneous Form 4 and reports a disposition of 3,737 common shares on 07/24/2025.

How many Processa Pharmaceuticals (PCSA) shares does Justin Yorke beneficially own after the reported transaction?

The filing reports indirect beneficial ownership of 12,400 shares via a Directed Trust Company account and 31,232 shares via Richland Fund, LLC.

Does the Form 4/A disclose any derivative securities for PCSA?

Yes. It discloses warrants exercisable for common stock at a $0.65 exercise price, expiring on 01/29/2030, covering 12,400 and 6,200 underlying shares.

Who signed the amended Form 4 for Justin Yorke?

The form is signed by Justin W. Yorke via attorney-in-fact John J. Wolfel on 09/18/2025.

What is the reporting person's relationship to Processa Pharmaceuticals (PCSA)?

The filing identifies Justin W. Yorke as a Director of Processa Pharmaceuticals, Inc.